PMV Pharmaceuticals (PMVP) FDA catalyst dates

FreeBioList tracks 2 upcoming catalysts for PMV Pharmaceuticals (PMVP, listed on Nasdaq). Both concern Rezatapopt (TP53 Y220C-mutant solid tumours; Platinum-resistant ovarian cancer, TP53 Y220C).

First on the list: the Phase 2 readout for Rezatapopt (TP53 Y220C-mutant solid tumours), guided by the company to Q4 2026. By stage, the upcoming rows are 1 Phase 2 readout and 1 Regulatory submission.

Both rows link to SEC filings (8-K or 6-K). Both have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.

Background reading: Clinical trial phases explained: Phase 1 to Phase 4; NDA vs BLA: the two kinds of US drug application.

Company ▾	Drug ▾	Effect / indication	Next catalyst ▾	Phase / type ▾	Status ▾	Source	Options
PMV Pharmaceuticals PMVP · Nasdaq	Rezatapopt	TP53 Y220C-mutant solid tumours	Q4 2026 company guidance	Phase 2 readout	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing states PMV "plans to provide an update on all PYNNACLE Phase 2 pivotal trial cohorts at a medical conference in fourth quarter of 2026." Source: 8-K exhibit 99.1, filed 31 Aug 2026 · verified 12 Sep 2026
PMV Pharmaceuticals PMVP · Nasdaq	Rezatapopt	Platinum-resistant ovarian cancer, TP53 Y220C	Q1 2027 company guidance	Regulatory submission	Verified	8-K exhibit 99.1 ↗	Yes
Notes — Filing states: "The Company anticipates submitting an NDA in the first quarter of 2027" under accelerated approval. Source: 8-K exhibit 99.1, filed 31 Aug 2026 · verified 12 Sep 2026

Companies working on related conditions

Context Therapeutics (CNTX)Platinum-resistant ovarian cancer (Claudin 6 x CD3); Urothelial, colorectal and triple-negative breast cancer (Nectin-4 x CD3)
Verastem Oncology (VSTM)KRAS G12D-mutant solid tumours; Recurrent low-grade serous ovarian cancer
Aktis Oncology (AKTS)Urothelial and Nectin-4 expressing solid tumours (radiopharmaceutical); Metastatic castration-resistant prostate cancer (B7-H3 radiopharmaceutical)
Aprea Therapeutics (APRE)Advanced solid tumours (WEE1 inhibitor)
Arvinas (ARVN)KRAS G12D-mutant solid tumours (degrader); Relapsed/refractory non-Hodgkin lymphoma (BCL6 degrader); Parkinson’s disease (LRRK2 degrader) — biomarker data; Kenn
Compass Therapeutics (CMPX)Biliary tract cancer (DLL4 x VEGF-A bispecific); TNBC, NSCLC and Hodgkin lymphoma post-checkpoint (PD-1 x PD-L1); Solid tumours (PD-1 x VEGF-A bispecific)

Also due in Q4 2026

Spyre Therapeutics (SYRE)Phase 2 readout for SPY072, Q4 2026
Structure Therapeutics (GPCR)Phase 2 readout for Aleniglipron, Q4 2026
Zura Bio (ZURA)Phase 2 readout for Tibulizumab (ZB-106), Q4 2026
Jasper Therapeutics (JSPR)Phase 2 readout for KP-104, Q4 2026
Rapport Therapeutics (RAPP)Phase 2 readout for RAP-219, Oct 2026
SELLAS Life Sciences Group (SLS)Phase 2 readout for SLS009 (tambiciclib), Q4 2026